A study found that a minimally invasive procedure could save limbs from amputation in severe vascular disease sufferers.
A study published in the New England Journal of Medicine has shown that there may finally be an alternative to amputation for patients suffering from chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease.
The PROMISE II US pivotal clinical trial found that minimally invasive LimFlow therapy enabled most patients to avoid amputation and experience wound healing. The procedure is designed to bypass blocked arteries in the leg and rush blood back into the foot through the veins.
The study, co-led by University Hospitals (UH) Harrington Heart & Vascular Institute, could lead to the first FDA approval of a therapy giving thousands of patients hope for an alternative to limb loss.
“LimFlow is a unique and novel alternative to major amputation, providing hope where previously there has been none,” said Mehdi Shishehbor, DO, MPH, PhD, president of UH Harrington Heart & Vascular Institute, and Angela and James Hambrick chair in Innovation, as well as lead author and co-principal investigator of the study in a release. “The results from this study are excellent and it’s very clear that LimFlow is a powerful tool for avoiding amputation.”
In the paper investigators evaluated 105 CLTI patients who were treated with transcatheter arterialization of the deep veins (TADV) using the LimFlow therapy. All patients were facing inevitable amputation before the procedure.
At 6 months post-procedure, 76% of patients were able to keep their leg (also called limb salvage). Within the same time period, 76% of patients had completely healed or healing wounds. Freedom from all-cause mortality was 87% at 6 months.
CLTI represents the end stage of peripheral artery disease, when poor circulation in the limb causes symptoms including numbness, and absent or diminished pulse in the feet or legs. Open sores, skin infections or ulcers that will not heal can cause gangrene and extreme pain.
It is estimated that 2 million Americans may be living with CLTI and, for the many with comorbidities like diabetes, treatments such as bypass surgery or endovascular revascularization may not be feasible. For these patients with no other options, the limb begins to turn black and die, and amputation may become imminent.
“Although this disease has existed for decades, research and innovations in treatment options have been lacking,” said Shishehbor. “We want to improve our patients’ lives, so we don’t take amputation lightly. While it can alleviate some issues related to disease, it brings its own challenges which can include disability, emotional distress, and even death.”
The Amputee Coalition of America estimates more than 500 patients undergo an amputation every day. Around 30% of amputees experience depression or anxiety. Amputees can have “phantom pain” in the missing limb that causes stabbing, burning or shooting sensations. Nearly half of all patients with vascular disease will die within 5 years after amputation, which is higher than the 5-year mortality rates for breast cancer, colon cancer, and prostate cancer.
“Approximately 185,000 amputations occur in the United States each year and a staggering 3.6 million people will be living with limb loss by 2050,” said Dr Daniel Simon, cardiologist and president, Academic & External Affairs and chief scientific officer. “These results are potentially a game changer for these patients and their families.”
Photo courtesy of University Hospitals
